10244-24-3

Basic information

• Product Name: 4,4'-(6-chloropyriMidine-2,4-diyl)diMorpholine
• Synonyms: 4,4'-(6-chloropyriMidine-2,4-diyl)diMorpholine;6-Chloro-2,4-bis(4-Morpholinyl)pyriMidine;4-chloro-2,6-diMorpholinopyriMidine;2,4-Bis(morpholin-4-yl)-6-chloropyrimidine;4-[6-Chloro-2-(morpholin-4-yl)pyrimidin-4-yl]morpholine;Morpholine, 4,4'-(6-chloro-2,4-pyriMidinediyl)bis-;4-[4-Chloro-6-(morpholin-4-yl)pyrimidin-2-yl]morpholine;2,4-Dimorpholino-6-chloropyrimidine
• CAS NO: 10244-24-3
• Molecular Formula: C₁₂H₁₇ClN₄O₂
• Molecular Weight: 284.74198
• Mol File: 10244-24-3.mol
• Article Data: 27

Chemical Properties

• Melting Point: 139-142℃
• Boiling Point: 508.7±60.0 °C(Predicted)
• Appearance: /
• Density: 1.327±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.10±0.50(Predicted)
• CAS DataBase Reference: 4,4'-(6-chloropyriMidine-2,4-diyl)diMorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4'-(6-chloropyriMidine-2,4-diyl)diMorpholine(10244-24-3)
• EPA Substance Registry System: 4,4'-(6-chloropyriMidine-2,4-diyl)diMorpholine(10244-24-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 10244-24-3(Hazardous Substances Data)

Usage

General Description

"4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine" is a specific chemical compound that falls under the category of organochlorides and morpholines. Organochlorides are organic compounds containing at least one chloroatom, while morpholines are heterocyclic organic compounds featuring a six-member ring with four carbon atoms and one nitrogen atom. In its raw form, it may appear as a crystalline solid or a liquid. The main uses of this chemical compound are not widely reported but, like many organochlorides and morpholines, it may be involved in the synthesis process of other complex chemicals or pharmaceutical substances. As with all chemicals, it must be handled carefully to prevent harmful effects. More specific information, like its physical and chemical properties or safety measures, can usually be found in its Material Safety Data Sheet (MSDS).

Upstream product

• 110-91-8 morpholine 
• 52127-83-0 4-(2,6-dichloropyrimidin-4-yl)morpholine 
• 3764-01-0 2,4,6-trichloropyrimidine 
• 10397-13-4 4,6-dichloro-2-(morpholine-4-yl)pyrimidine 

Downstream Products

• 1399879-64-1 (E)-4,4'-(6-(2-((1-(4-fluorobenzyl)-1H-indol-3-yl)methylene)hydrazinyl)pyrimidine-2,4-diyl)dimorpholine 
• 1399879-69-6 (E)-4,4'-(6-(2-((1-(3-(trifluoromethyl)benzyl)-1H-indol-3-yl)methylene)hydrazinyl)pyrimidine-2,4-diyl)dimorpholine 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

Three series of substituted pyrimidines were designed and synthesized. All target compounds were screened for kinase inhibitory activities against PI3Kα, and most IC50 values were found within the nanomolar range. Compounds 5d and 5p displayed

Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer

The development of inhibitors targeting the PI3K-Akt-mTOR signaling pathway has been greatly hindered by the on-target AEs, such as hyperglycemia and hepatotoxicities. In this study, a series of diaryl urea derivatives has been designed and synthesized based on clinical candidate gedatolisib (6aa), and most of the newly synthesized derivatives showed kinase inhibitory and antiproliferative activities within nanomolar and submicromolar level, respectively. The terminal l-prolineamide substituted derivative 6 ab showed 8.6-fold more potent PI3Kα inhibitory activity (0.7 nM) and 4.6-fold more potent antiproliferative effect against HCT116 cell lines (0.11 μM) compared with control 6aa. The potential antitumor mechanism and efficacy of 6 ab in HCT116 xenograft models have also been evaluated, and found 6 ab showed comparable in vivo antitumor activity with 6aa. The safety investigations revealed that compound 6 ab exhibited more safer profiles in the selectivity of liver cells (selectivity index: >6.6 vs 1.85) and blood glucose regulation than 6aa. In addition, the in vitro stability assays also indicated our developed compound 6 ab possessed good metabolic stabilities.

TREATMENT OF SKIN LESIONS

The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1 X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1alkoxyC1-C3alkyl, CN, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue -R5R6- selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue-R8R9- selected from Ci-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CH2CH2-O-; with the proviso that at least one of R1 and R2is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a skin lesion in a subject.